New drug trial targets heart inflammation in sarcoidosis patients
NCT ID NCT06868381
First seen Feb 19, 2026 · Last updated Jun 15, 2026 · Updated 16 times
Summary
This early-phase study tests whether baricitinib, taken with a steroid-sparing medication, can reduce active inflammation in the heart caused by sarcoidosis. Ten adults with cardiac sarcoidosis will take the drug for up to 16 weeks and undergo PET scans to see if heart inflammation improves. The goal is to control the disease, not cure it, as ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304-2210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.